Based on the Bionomics Ltd ADR stock forecast from 0 analysts, the average analyst target price for Bionomics Ltd ADR is not available over the next 12 months. Bionomics Ltd ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Bionomics Ltd ADR is Bearish, which is based on 2 positive signals and 7 negative signals. At the last closing, Bionomics Ltd ADR’s stock price was USD 0.24. Bionomics Ltd ADR’s stock price has changed by -24.82% over the past week, -12.59% over the past month and -81.17% over the last year.
No recent analyst target price found for Bionomics Ltd ADR
No recent average analyst rating found for Bionomics Ltd ADR
Company Overview Bionomics Ltd ADR
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders; and Nav1.7/1.8 inhibitors which is in preclinical trial for the potential treatment of chronic pain without the liability of addiction associated with opioid treatment. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia. Read Less
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the...Read More
Frequently Asked Questions About Bionomics Ltd ADR (BNOX) Stock
Stock Target Advisor's fundamental analysis for Bionomics Ltd ADR's stock is Bearish.
Unfortunately we do not have enough data on BNOX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNOX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BNOX's stock to indicate if its overvalued.
The last closing price of BNOX's stock was USD 0.24.
The most recent market capitalization for BNOX is USD 5.84M.
Unfortunately we do not have enough analyst data on BNOX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bionomics Ltd ADR's stock.
As per our most recent records Bionomics Ltd ADR has 8 Employees.
Bionomics Ltd ADR's registered address is 200 Greenhill Road, Eastwood, SA, Australia, 5063.
You can get more information about it from Bionomics Ltd ADR's website at https://www.bionomics.com.au.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bionomics Ltd ADR (BNOX) Stock
Stock Target Advisor's fundamental analysis for Bionomics Ltd ADR's stock is Bearish.
Unfortunately we do not have enough data on BNOX's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BNOX's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on BNOX's stock to indicate if its overvalued.
The last closing price of BNOX's stock was USD 0.24.
The most recent market capitalization for BNOX is USD 5.84M.
Unfortunately we do not have enough analyst data on BNOX's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Bionomics Ltd ADR's stock.
As per our most recent records Bionomics Ltd ADR has 8 Employees.
Bionomics Ltd ADR's registered address is 200 Greenhill Road, Eastwood, SA, Australia, 5063.
You can get more information about it from Bionomics Ltd ADR's website at https://www.bionomics.com.au.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BNOX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
